Table 1.
Sociodemographic and clinical characteristics of the weighted study sample.
Table 2.
Sociodemographic and clinical characteristics of people with CKD 3–5 defined by eGFR (from MDRD and CKDEPI equations) and after targeted addition of cystatin C.
Fig 1.
Prevalence of eGFR<60ml/min/1.73m2 by age grouping and serum creatinine eGFR estimating method.
Fig 2.
Effect of the use of different combinations of measures on the risk profile and estimated prevalence of CKD.
Table 3.
Characteristics of populations with selected combinations of biomarkers following testing with cystatin C.
Table 4.
Estimated prevalence and associations of cystatin C CKD 3–5 (Grubb-defined eGFR <60ml/min/1.73m2) with socio-economic and clinical factors.